Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

Co-authors reported relationships with the NIH, Veracyte, and Adela. Mark disclosed relationships with Intuitive Surgical, ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...